
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents
Keywords: محدوده بین محدب; IL12; IL23; Inflammatory Bowel Disease; Immunosuppressant; CD; Crohn's disease; CRP; C-reactive protein; IQR; interquartile range; TNF; tumor necrosis factor;